Tag Archive for: conference attendance

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare Conference Location: London One-on-one meetings: Wednesday, November 15, 2023 Participants: Mai-Britt Zocca, PhD, President and […]

Lytix Biopharma presenting at major investor conferences in London and Stockholm in November

Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Øystein Rekdal, CEO, will deliver oral presentations to institutional investors in London at the LSX Inv€$tival Showcase on the 13th of November, and attend the Jefferies Healthcare Conference on the 14th -16th November. Investors interested […]

Vicore to Present at the Stifel 2023 Healthcare Conference

Stockholm, November 7, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference in New York, NY. Read more…

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

• Abstract demonstrates efficacy of combination antibiotics with STIMULAN beads compared to intraarticular concentrations of IV antibiotic alone • Mr. Robert Morley and Dr. Yvonne Achermann to speak on the merits of local antibiotic delivery Keele, UK, 5 October 2023 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for […]

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences. Read more…